These puzzled observations also implicate that these fusion genes may bypass the AR regulation in advanced prostate cancer, and also these fusion genes-positive patients are susceptible to evolve into therapy-resistant and androgen-independent metastatic disease. This evidence concerns the gene AR and prostate carcinoma.